ACF is currently working on future revisions to this information collection, which will be submitted to OMB for review and approval in 2025. Notices inviting public comment on those revisions will accompany that request, but comments received in response to this notice could also inform those revisions. Through this request process minor discrepancies were noted between the OMB-approved instruments and those currently in use. These minor errors were fixed in the versions included with the request to OMB.

Respondents: General Departmental (GDSRAE), State (SSRAE), and Competitive (CSRAE) grant recipients, their subrecipients, and program participants.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Avg. burden per response (in hours)	Total/ annual burden (in hours)
(1) Participant Entry Survey				
GDSRAE participants	126,130	1	0.1333	16,813
SSRAE participants	317,633	1	0.1333	42,340
CSRAE participants	20,136	1	0.1333	2,684
(2) Participant Exit Survey				
GDSRAE participants	100,904	1	0.1667	16,821
SSRAE participants	254,106	1	0.1667	42,360
CSRAE participants	16,109	1	0.1667	2,685
(3) Performance reporting data entry form: grant recipients				
GDSRAE grant recipients	119	2	16	3,808
SSRAE grant recipients	39	2	16	1,248
CSRAE grant recipients	34	2	16	1,088
(4) Performance reporting data entry form: subrecipients				
GDSRAE subrecipients	252	2	13	6,552
SSRAE subrecipients	426	2	13	11,076
CSRAE subrecipients	63	2	13	1,638

Estimated Total Annual Burden Hours: 149,113.

Authority: 42 U.S.C. 1310.

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2024–27053 Filed 11–19–24; 8:45 am]

BILLING CODE 4184–83–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–P–4163]

Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** on October 16, 2024. The document announced that NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g), was not withdrawn from sale for reasons of safety or effectiveness. The document incorrectly listed the dosage strength as 100 g. The correct strength is 100 milligrams (mg). This notice corrects that error.

FOR FURTHER INFORMATION CONTACT: Awo Archampong-Gray, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6243, Silver Spring, MD 20993–0002, 301–796–0110, *Awo.Archampong-Gray@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: In FR Doc. 2024–23811, published in the **Federal Register** of Wednesday, October 16, 2024 (89 FR 83504), appearing on pages 83504 and 83505, the following corrections are made:

1. On page 83504, in the second column, the title of the document is corrected to read ''Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness.''

2. On page 83504, in the third column, in the **SUMMARY**, in the first paragraph, ''NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g),'' is corrected to read ''NOXAFIL (posaconazole) delayed-release tablets, 100 milligrams (mg),''.

3. On page 83505, in the first and second columns, all uses of ''100 g'' are corrected to read ''100 mg''.

Dated: November 7, 2024.

Kimberlee Trzeciak,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2024–27082 Filed 11–19–24; 8:45 am]

BILLING CODE 4164–01–P